Promega HaloTag™ Vectors 

Description

• All vectors are compatible with Promega Flexi Vector System, directional cloning method for protein-coding sequences
• Vectors designated “pFC” are configured to append HaloTag 7 to carboxy-terminus of protein fusion partner
• Vectors designated “pFN” are configured to append HaloTag 7 to amino-terminus of protein fusion partner

Vectors for Mammalian Protein Expression

• Vectors contain either full-length (pFC14, pFN21) or modified (pFC15, pFC16, pFC17, pFN22, pFN23, pFN24) human cytomegalovirus (CMV) promoter
• The modified CMV promoter, which contains various deletions, provides varying levels of protein expression levels, depending on protein of interest and cell type

Vectors for E. coli and Cell-Free Protein Expression

• pFN18 vectors provide T7 RNA polymerase-driven protein expression in E. coli or in cell-free translation systems
• pFN19 vectors provide T7 RNA polymerase-driven protein expression in E. coli ( ∽two- to four-fold lower protein expression compared to pFN18 vectors) or T7 or SP6 RNA polymerase-driven protein expression in cell-free translation systems
• pFC20 vectors provide T7 RNA polymerase-driven protein expression in E. coli or T7 or SP6 RNA polymerase-driven protein expression in cell-free translation systems

Cellular imaging, Protein:protein interaction, Protein:DNA interaction.

• Patent pending.
• For research use only. Researchers may use this product in their own research and they may transfer derivatives to others for research use provided that at the time of transfer a copy of this label license is given to the recipients and recipients agree to be bound by the terms of this label license. Researchers shall have no right to modify or otherwise create variations of the nucleotide sequence of the HaloTag gene. Researchers may however clone heterologous DNA sequences at either or both ends of said HaloTag gene so as to create fused gene sequences provided that the coding sequence of the resulting HaloTag gene has no more than four (4) deoxynucleotides missing at the affected terminus when compared to the intact HaloTag gene sequence. In addition, researchers must do one of the following: (1) use Promega HaloTag ligands, which can be modified or linked to Promega or customer-supplied moieties, or (2) contact Promega to obtain a license. No other use or transfer of this product or its derivatives is authorized without the express, written consent of Promega including, without limitation, Commercial Use. Commercial Use means any and all uses of this product and derivatives by a party for monetary or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research. With respect to such Commercial Use, or any diagnostic, therapeutic or prophylactic uses, please contact Promega for supply and licensing information. If the purchaser is not willing to accept the conditions of this limited use statement, Promega is willing to accept return of the unopened product and provide purchaser with a full refund. However, in the event that the product is opened, then purchaser agrees to be bound by the conditions of this limited use statement.
• For research use only. Persons wishing to use this product or its derivatives in other fields of use, including without limitation, commercial sale, diagnostics or therapeutics, should contact Promega Corporation for licensing information.
• Mfr. Nos. G2841, G2851, G2861, G2871, G2881, G2981, G3780, G2751, G2681, G1891, G1841, G1681, G1691: Licensed for research and laboratory use only under U.S. Patent 5,547,862.